Stockwatch: New antibiotics: easy to say; hard to do
This article was originally published in Scrip
Executive Summary
Most of the contemporary challenges for the western world are easy to identify, but difficult to resolve. These include the pensions time-bomb, the obesity epidemic, the patent cliff, the European sovereign debt crisis and the lack of new antibiotics. While the European sovereign debt crisis lurched into a significantly worse position this week, two other announcements proposed remedies to two of these challenges.
You may also be interested in...
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.